NCT03233646 Retinal Imaging in Neurodegenerative Disease
| NCT ID | NCT03233646 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2017-07-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2017-07-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Eligibility Criteria
Inclusion Criteria: * Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome) * Adults without neurodegenerative disease Exclusion Criteria: * Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition. * Eyes that have had intraocular surgery, other than cataract surgery. If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.
Contact & Investigator
Sharon Fekrat, MD FACS FASRS
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT03233646 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03233646 currently recruiting?
Yes, NCT03233646 is actively recruiting participants. Contact the research team at imind@duke.edu for enrollment information.
Where is the NCT03233646 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT03233646 clinical trial?
NCT03233646 is sponsored by Duke University. The principal investigator is Sharon Fekrat, MD FACS FASRS at Duke University. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.